Moderate hyperprolactinemia is associated with survival in patients with acute graft-versus-host disease after allogeneic stem cell transplantation

Hematology

Volumn 17, Issue 2, 2012, Pages 85-92

  Parra, Adalberto ^a   Ramírez Peredo, Jorge ^a   Reyes, Enrique ^a   Hidalgo, Rocío ^a   Macías Gallardo, Julio ^b   Lutz Presno, Julia ^b   Ruiz Argüelles, Alejandro ^c   Garza, Eduardo ^c   Infante, Eduardo ^d   Gutiérrez Aguirre, César H ^e   Salazar Riojas, Rosario ^e   Villarreal, Jesús Z ^e   Gómez Almaguer, David ^e   Ruiz Argüelles, Guillermo J ^b,c  

^a INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^b CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

^c Laboratorios Clinicos de Puebla   (Mexico)

^d Beckton Dickinson Mexico   (Mexico)

^e HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Acute GVHD; Allo HSCT; Cytokines profile; Dopaminergic tone; Prolactin

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; PROLACTIN; TUMOR NECROSIS FACTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERPROLACTINEMIA; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; TH1 CELL;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PROLACTIN; SEVERITY OF ILLNESS INDEX; SIBLINGS; SURVIVAL RATE; TH1-TH2 BALANCE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84862975860     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13221316477930     Document Type: Article

References (45)

1. Thomas ED. Hematopoietic stem cell transplantation. Sci Am. 1995;272:38-47.
2. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003;21:149-161.
3. Lunn RA, Sumar N, Bansal AS, Treleaven J. Cytokine profiles in stem cell transplantation: possible use as a predictor of graftversus- host disease. Hematology. 2005;10:107-114.
4. Krenger W, Ferrara JL. Graft-versus-host disease and the Th1/ Th2 paradigm. Immunol Res. 1996;15:50-73.
5. Hinterberger-Fischer M, Kier P, Spona J, Sebesta C, Tiefengraber E, Habertheuer KH, et al. Prolactin: a possible mediator of graft-versus-host disease following allogeneic bone marrow transplantation in humans. Bone Marrow Transplant. 1994;14:403-406.
6. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation. 1997;4:171-180.
7. Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon- gamma by natural killer and T cells. Ann NY Acad Sci. 2000;917:505-513.
8. Richards SM, Murphy WJ. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J Neuroimmunol. 2000;109:56-62.
9. Welniak LA, Richards SM, Murphy WJ. Effects of prolactin on hematopoiesis. Lupus. 2001;10:700-705.
10. Sun R, Gault RA, Welniak LA, Tian ZG, Richards S, Murphy WJ. Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant. 2003;9:426-434.
11. Sun R, Zhang J, Zhang C, Zhang I, Liang S, Sun A, et al. Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice. Cell Mol Biol. 2004;1:129-136.
12. Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci. 1996;59:599-614.
13. Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Biomed. 2007;78(Suppl. 1):255-261.
14. Reber PM. Prolactin and immunomodulation. Am J Med. 1993; 95:637-644.
15. Ben-Jonathan N. Dopamine: a prolactin inhibiting hormone. Endocr Rev. 1985;6:564-589.
16. Quigley ME, Judd SJ, Gilliland GB, Yen SSC. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and in women with hyperprolactinemic anovulation. J Clin Endocrinol Metab. 1979;98:718-720.
17. Parra A, Ramírez-Peredo J, Larrea F, Cabrera V, Coutiño B, Torres I, et al. Decreased dopaminergic tone and increased basal bioactive prolactin in men with immunodeficiency virus infection. Clin Endocrinol (Oxf). 2001;54:731-738.
18. Parra A, Ramírez-Peredo J, Hidalgo R, Morales-Toquero A, Velásquez-Ramírez G, Ruiz-Argüelles A, et al. Altered functional status of the hypothalamic dopaminergic tone in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a pilot study. Biol Blood Marrow Transplant. 2006;12:566-572.
19. Yen SSC. Prolactin in human reproduction. In: Yen SSC, Jaffe RB, (eds.) Reproductive endocrinology. 3rd ed. Philadelphia: Saunders; 1991. p. 357-388.
20. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Autologous peripheral hematopoietic stem cell transplantation restores hemopoietic function following marrow ablative therapy. Blood. 1998;71:723-727.
21. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory, Principles, applications and problems. Ann Biol Clin. 1992;50: 735-743.
22. Ruiz-Argüelles A, Orfao A. Caracterización y evaluación de células totipotenciales en sangre periférica y médula ósea. In: Ruiz-Argüelles GJ, San-Miguel JF, (eds.) Actualización en Leucemias. 1st ed. México City: Editorial Médica Panamericana; 1996. p. 79-82.
23. Ruiz-Argüelles GJ, Gómez-Almaguer D, López-Martínez B, Cantú-Rodríguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica. 2002;87:894-896.
24. Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, et al. Latin American Cooperative Oncohematology Group. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant. 2005;36:1043-1047.
25. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA. 1996;83:2934-2938.
26. Yam P, Petz L, Knowlton R, Wallace R, Stock A, deLange G, et al. Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation. Transplantation. 1987;43:399-407.
27. Tai MM. A mathematical model for the determination of total area under glucose tolerance and oter metabolic curves. Diabetes Care. 1994;17:152-154.
28. Suginami H, Hamada K, Yano K, Kurada G, Matsuura S. Ovulation induction with bromocriptine in normoprolactinemic anovulatory women. J Clin Endocrinol Metab. 1996;62:899-903.
29. Reinthaller A, Neunteufel W, Bieglmayer C, Fischl F. The metoclopramide- provocation test for prediction of transient hyperprolactinemia during cycle stimulation. Fertil Steril. 1990;53: 368-371.
30. Kast R. Blocking of cyclosporine immunosupression by neuroleptics. Transplantation. 1989;47:1095-1096.
31. Clevenger CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells of the immune system. J Endocrinol. 1998;157:187-197.
32. Gala RR. The physiology and mechanisms of stress-induced changes in prolactin secretion in the rat. Life Sci. 1990;46: 1407-1420.
33. Kant GJ, Bauman RA, Anderson SM, Mongey EH. Effects of controllable and uncontrollable chronic stress on stressresponsive plasma hormones. Physiol Behav. 1992;51:1285-1288.
34. Weimann E, Baixeras E, Zamzani M, Kelly P. Prolactin blocks glucocorticoid-induced cell death by inhibiting the disruption of the mitocondrial membrane. Leuk Res. 1999;23:751-762.
35. Parra A, Ramírez-Peredo J, Larrea F, Pérez-Romano B, Cabrera V, Torres I, et al. Serum prolactin is associated with apoptosis in men with immunodeficiency virus infection. Immunol Cell Biol. 2001;79:285-290.
36. Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR. Rapid modulation of the apoptosis regulatory genes, bcl-2 and bax by prolactin in rat Nb2 lymphoma cells. Endocrinology. 1996;137:5456-5462.
37. Krumenacker JS, Buckley DJ, Leff MA, McCormack JT, De Jong G, Gout PW, et al. Prolactin regulated apoptosis of Nb2 lymphoma cells: pim-1, bcl-2, and bax expression. Endocrine. 1998;9:163-170.
38. Parra A, Reyes-Terán G, Ramírez-Peredo J, Benedict J, Quiroz V, Cárdenas M, et al. Differences in nocturnal basal and rhythmic prolactin secretion in untreated compared to treated HIV-infected men are associated with CD4+ T-lymphocytes. Immunol Cell Biol. 2004;82:24-31.
39. Clevenger CV, Rusell DA, Appasamy PM, Pristowsky MB. Regulation of interleukin-2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA. 1990;87:6460-6464.
40. Clevenger CV, Sillman AL, Hanley-Hyde J, Pristowsky MB. Requirement for prolactin during cycle regulated gene expression in cloned T-lymphocytes. Endocrinology. 1992;130: 3216-3222.
41. Matera L, Cesano A, Bellone G, Oberholtzer E. Modulatory effect of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav Immun. 1992;6: 409-417.
42. Fowler DH, Gress RE. Th2 and Tc cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221-234.
43. Mariotti J, Foley J, Ryan K, Buxhoeveden N, Kapoor V, Amarnath S, et al. Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood. 2008;112:4765-4775.
44. Hinterberger-Fisher M, Hinterberger W. Blood stem cell transplantation for breast cancer: new approaches using pre-peripost transplant immunotherapy. Expert Opin Biol Ther. 2001; 1:1029-1048.
45. Hernández-Ruiz J, Farfán B, Córdoba J, Parra A, Ramírez J, Kershenobich D, et al. Effect of prolactin in-vitro and in-vivo on perforin and trail expression in human NK lymphocytes. Eur J Immunol. 2009;39(Suppl. 1):S-345.